Ultimately, they demonstrate that pharmacological suppression of the PI3K/AKT/mTOR pathway destabilizes SOX9 in a GSK3/FBW7-dependent manner, enabling medulloblastoma cells susceptible to cytostatic therapy (Suryo Rahmanto et al., 2016). This evidence concerns the gene SOX9 and medulloblastoma.